Home / Business and Economy / FDA Clears Jubilant Pharmova's Spokane Facility
FDA Clears Jubilant Pharmova's Spokane Facility
12 Sep
Summary
- Spokane facility classified as Voluntary Action Indicated by US FDA.
- Inspection at the contract manufacturing facility concluded in June 2026.
- No administrative or regulatory action is expected from the FDA.
The US FDA has classified the Spokane contract manufacturing facility of Jubilant HollisterStier LLC as 'Voluntary Action Indicated' (VAI). This classification comes after an inspection conducted from June 8, 2026, to June 17, 2026. The VAI designation means the FDA identified some objectionable conditions or practices during the inspection.
However, the agency does not plan to pursue administrative or regulatory action against the facility. Jubilant Pharmova confirmed that the company is expected to voluntarily address the noted issues. Jubilant HollisterStier LLC is a subsidiary of Jubilant Pharma Holding Inc.
Disclaimer: This story has been auto-aggregated and auto-summarised by a computer program. This story has not been edited or created by the Feedzop team.
